Covalis Capital’s Biote Corp BTMD Stock Holding History

Covalis Capital’s Portfolio BTMD Stock Details BTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$195K	–	86
2021 Q3	$195K	Hold	20,000	–	–	0.05%	92
2021 Q2	$195K	Buy	+20,000	New	+$196K	0.06%	95

Other funds holding BTMD

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

SRF

Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Covalis Capital's BTMD Position: Q4 2021 in Review

Covalis Capital sold out of Biote Corp (BTMD) in Q4 2021, closing a stake of 20,000 shares — an estimated $195K sold.

Covalis Capital first reported a position in BTMD in Q2 2021 and held it in 2 quarters. The position peaked at $195K in Q3 2021. 78 funds tracked by Wall St. Rank hold BTMD as of Q4 2021.

Covalis Capital reported no remaining Biote Corp position as of Q4 2021 after selling out during the quarter.
Covalis Capital sold 20,000 Biote Corp shares in Q4 2021, an estimated $195K.
Covalis Capital first reported a position in Biote Corp in Q2 2021 and held it in 2 quarters.
Covalis Capital's Biote Corp position peaked at $195K in Q3 2021.
78 funds tracked by Wall St. Rank held Biote Corp as of Q4 2021.

Based on Covalis Capital's 13F filing for Q4 2021, filed 14 Feb 2022.